Bumetanide Injection shortage
Bumetanide Injection is currently listed in shortage by the FDA. The FDA lists 12 affected products. The reported reason: Demand increase for the drug. This page was last refreshed from FDA data on Sep 21, 2026.
Bumetanide injection has been in short supply for over a year due to higher demand. All strengths still have at least some supply available, and other manufacturers not reporting a shortage also list this medicine.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Bumetanide Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 16, 2026Currently in shortage12 of 12 products affected.
-
Sep 15, 2026FDA refreshed this shortage record2 products updated.
-
Sep 3, 2026FDA refreshed this shortage record2 products updated.
-
Aug 18, 2026FDA refreshed this shortage record2 products updated.
-
Jan 31, 2018More presentations reported6 more products added to the shortage.
-
Dec 13, 2017First reported to the FDA6 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10) | — | Available | Check wholesalers for inventory | — |
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04) | — | Available | Check wholesalers for inventory | — |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10) | — | Available | Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released. | — |
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10) | — | Unavailable | Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
Manufacturer: MSN Laboratories Private Limited 📞 855-668-2369; [email protected] 4 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07) | — | Available | — | — |
| Current | Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01) | — | Available | — | — |
| Current | Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07) | — | Available | — | — |
| Current | Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01) | — | Available | — | — |
Manufacturer: Mullan Pharmaceutical Inc. 📞 800-673-9839 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2) | — | Available | — | — |
| Current | Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2) | — | Available | — | — |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 2 NDCS click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10) | — | Available | — | — |
| Current | Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04) | — | Available | — | — |
These rows are manufacturer reports to the FDA for Bumetanide Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Bumetanide Injection? options further down this page.
Why is Bumetanide Injection in shortage?
The main reason Bumetanide Injection is on the FDA shortage list is that more people need it than the usual supply can keep up with — what the FDA calls a "demand increase." For Hikma Pharmaceuticals specifically, one of their 0.25 mg/1 mL presentations is currently unavailable because of this higher-than-normal demand, and they expect additional lots of that product to be ready around September 2026. Their other 0.25 mg/1 mL presentation is still available, with more manufacturing scheduled to help meet demand.
It's worth knowing that this shortage report covers multiple manufacturers, and several of them — including MSN Laboratories, Fresenius Kabi, Mullan Pharmaceutical, and Sagent Pharmaceuticals — are reporting their Bumetanide Injection products as currently available. Fresenius Kabi notes that you may need to check with wholesalers to find their inventory.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Bumetanide Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Bumetanide Injection?
Bumetanide Injection is currently on the FDA shortage list, but supply overall remains strong, so this should have little effect on your care.
Here is the part that matters most for finding what you take: every strength on this record still has an available source. That includes the 0.25 mg/mL vials in the 4 mL, 10 mL, and 2.5 mg/10 mL sizes, as well as the 1 mg/4 mL size. No strength is currently listed with no source at all. One manufacturer marked a single lot as temporarily unavailable, with additional lots expected around September 2026, but four other makers still report the same medicine as available.
The reported reason is simply higher demand. All five manufacturers on this record are still supplying, and more lots are scheduled to be made.
What you can do:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers, since supply exists.
- If your usual product is briefly out, this same medicine is available from other makers your pharmacy may be able to source, though it may not be in local stock.
- If a specific product cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This reflects national data and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Bumetanide Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Bumetanide Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-6284-10 |
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | Camber Pharmaceuticals, Inc. | 31722-0368-32 |
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | GLENMARK PHARMACEUTICALS INC., USA | 68462-0469-54 |
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | Lupin Pharmaceuticals, Inc. | 70748-0323-10 |
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | Bryant Ranch Prepack | 72162-2632-02 |
| Bumetanide | BUMETANIDE .25 mg/mL | Injection · Intramuscular, Intravenous | Civica, Inc. | 72572-0040-10 |
Alternative dosage forms of Bumetanide
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Bumetanide .25 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Sagent | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Camber | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Fresenius | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Qilu | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Gland | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | GLENMARK | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Lupin | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Bryant | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Novadoz | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Civica, | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Mullan | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Fresenius | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Gland | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Novadoz | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Civica, | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Hikma | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Anthea | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Camber | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Qilu | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | GLENMARK | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | HF | 4 ml | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Bryant | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Mullan | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Cardinal | 5 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Cardinal | 5 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Anthea | 10 vials | — | AP | FDA listed |
| Bumetanide .25 mg/mL | Civica, | 10 vials | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Bumetanide Injection — that fall in the same broad treatment class (loop diuretics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other cardiovascular shortages
Bumetanide Injection shortage FAQs
Is Bumetanide Injection in shortage?
Why is Bumetanide Injection in shortage?
Which products are affected?
When will Bumetanide Injection be available again?
Can I still get Bumetanide somewhere?
What should I do if I take Bumetanide Injection?
Still have a question about the Bumetanide Injection shortage?
Ask a pharmacist about this shortage →View Bumetanide Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.